Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY016 injection in EGFR-expressing advanced solid tumors (Phase I/II)
CTR20260533Phase 2Active
- Sponsor
- Beijing Eastern Biotech
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JY016 in Nonhematologic neoplasms, pancreatic cancer (PC), non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC), colorectal cancer (CRC), sponsored by Beijing Eastern Biotech. Started Feb 2026; status: active.
02
Drugs
JY016
03
Conditions
Nonhematologic neoplasmspancreatic cancer (PC)non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20260533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260533.